Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction

• Status: Completed
• Trial end date: 2005-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with mild to moderate hypertension, dyslipidemia (imbalanced blood lipids) and decreased vascular dilatation, receiving a cholesterol lowering diet were given either valsartan or fluvastatin for 8 weeks. At week 8 all patients were administered a combination treatment with valsartan 160 mg and fluvastatin 80 mg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Fluvastatin; Valsartan

Criteria

Inclusion Criteria:

• Arterial hypertension

• Dyslipidemia

• Cholesterol lowering diet

Exclusion Criteria:

• Constant antihypertensive treatment

• Diabetes mellitus

• Myocardial infarction or stroke in the previous 3 months

Other inclusion and exclusion criteria may apply